Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/Metformin/Teneligliptin - Glenmark Pharmaceuticals

Next Previous
X
Search
Drug Profile

Dapagliflozin/Metformin/Teneligliptin - Glenmark Pharmaceuticals

Alternative Names: Dapagliflozin/Teneligliptin/Metformin - Glenmark Pharmaceuticals; Metformin/Dapagliflozin/Teneligliptin - Glenmark Pharmaceuticals; Metformin/Teneligliptin/Dapagliflozin - Glenmark Pharmaceuticals; Teneligliptin/Dapagliflozin/Metformin - Glenmark Pharmaceuticals; Teneligliptin/Metformin/Dapagliflozin - Glenmark Pharmaceuticals; Triple Drug FDC - Glenmark Pharmaceuticals; ZITA DM

Latest Information Update: 17 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Chlorobenzenes; Eye disorder therapies; Glucosides; Heart failure therapies; Ketones; Obesity therapies; Piperazines; Pyrans; Pyrazoles; Small molecules; Thiazolidines; Urologics
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 18 Oct 2023 Launched for Type 2 diabetes mellitus in India (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top